Recent Finacing
Recent Raise
Immune-Onc develops clinical-stage myeloid checkpoint–targeting antibody therapeutics against the LILRB family (IO-202, IO-108) for AML, CMML, and solid tumors, with industry and academic collaborations.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Immune-Onc Therapeutics.
